Skip Navigation



European Journal of Echocardiography Advance Access published online on May 7, 2008
European Journal of Echocardiography, doi:10.1093/ejechocard/jen160
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Rasmussen, V. G.
Right arrow Articles by Egeblad, H.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rasmussen, V. G.
Right arrow Articles by Egeblad, H.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2008. For permissions please email: journals.permissions@oxfordjournals.org

Ergotamine-derived dopamine agonists and left ventricular function in Parkinson patients: systolic and diastolic function studied by conventional echocardiography, tissue Doppler imaging, and two-dimensional speckle tracking

Vibeke Guldbrand Rasmussen1,*, Steen Hvitfeldt Poulsen1, Erik Dupont2, Karen Østergaard2, Gholamhossein Safikhany3 and Henrik Egeblad1

1 Department of Cardiology, Aarhus University Hospital, Skejby, DK-8200 Aarhus N, Denmark
2 Department of Neurology, Aarhus University Hospital, DK-8000 Aarhus C, Denmark
3 Department of Neurology, Holstebro Hospital, DK-7500 Holstebro, Denmark

Received 9 January 2008; accepted after revision 12 April 2008.

* Corresponding author. Tel: +45 89496234; fax: +45 89496009. E-mail address: vibeke.guldbrand{at}ki.au.dk


  Abstract

Aims: Ergot-derived dopamine agonists (EDDA) induce fibrotic heart valve disease. We aimed to investigate whether EDDA treatment also affects left ventricular (LV) function.

Methods and results: Myocardial function was evaluated in 110 Parkinson patients [mean age (63.4 ± 9.0 years)] treated for at least 6 months with either EDDA (n = 71) or non-EDDA (n = 39). LV ejection fraction did not differ between EDDA and non-EDDA patients [63 ± 4% vs. 65 ± 4% (ns)]. There was no difference in prevalence of diastolic dysfunction between EDDA and non-EDDA patients [7% vs. 8% (ns)]. Finally, averaged LV systolic myocardial strain and longitudinal displacement analysed by means of two-dimensional speckle tracking showed no difference between EDDA and non-EDDA patients [strain: 19 ± 3% vs. 19 ± 2% (ns) and longitudinal displacement: 12 ± 2 mm vs. 12 ± 2 mm (ns)]. Elevated p-NT-proBNP was found in 38% of EDDA patients and in 59% of non-EDDA patients (ns).

Conclusion: In contrast to the well-established association between EDDA treatment and valvular fibrosis, EDDA did not have a detectable adverse impact on myocardial systolic and diastolic function.

Keywords: Myocardial function; Fibrosis; Ergolines; Dopamine agonists


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.